Analysts' Recent Ratings Changes for Madrigal Pharmaceutical

A number of firms have modified their ratings and price targets on shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) recently: 2/26/2024 – Madrigal Pharmaceuticals was downgraded by analysts at B. Riley from a “neutral” rating to a “sell” rating. They now have a $155.00 price target on the stock, down previously from $204.00. 2/23/2024 – Madrigal […]

Related Keywords

United States , Brian Joseph Lynch , Roberte Waltermire , Piper Sandler , News Ratings For Madrigal Pharmaceuticals Inc Daily , Madrigal Pharmaceuticals , Deutsche Bank , York Mellon Corp , Wintrust Investments , Securities Exchange Commission , Institutional Investors Weigh In On Madrigal Pharmaceuticals , Jp Morgan Private Wealth Advisors , Madrigal Pharmaceuticals Inc , Madrigal Pharmaceuticals Price Performance , Charles Schwab Investment Management Inc , Exchange Commission , Joseph Lynch , New York Mellon Corp , Private Wealth Advisors , Schwab Investment Management , Madrigal Pharmaceuticals Inc Daily ,